Tavolixizumab

DB15042InvestigationalProtein Based Therapies

Tavolixizumab is under investigation in clinical trial NCT02318394 (A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 4
Curator reviewed
Also known as: HUMAN IgG1 KAPPA ANTI-HUMAN OX40 MONOCLONAL ANTIBODY MEDI0562 · IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENSTNFRSF4 (TUMOR NECROSIS FACTOR RECEPTOR (TNFR) SUPERFAMILY MEMBER 4, OX40, CD134)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY GAMMA1 HEAVY CHAIN (1-451) (CHIMERIC VH (MUS MUSCULUS IGHV3-8*02 -(IGHD)-HOMO SAPIEN · IMMUNOGLOBULIN G1, ANTI-(HUMAN CD134 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL MEDI0562 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MEDI0562 .KAPPA.-CHAIN, DIMER · Tavolimab
Code names: MEDI-0562

Resolves to

Compound

UNII4LU9B48U4DCAS1635395-25-3

Targets

P43489TNFRSF4

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tavolixizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account